Mantle Cell Lymphoma
Conference Coverage
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
Conference Coverage
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
Conference Coverage
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.
Conference Coverage
Avapritinib yields high response rate in patients with systemic mastocytosis
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
From the Journals
Rituximab key to survival after transplant for mantle cell lymphoma
The benefit of rituximab “stands out, and adds to the increasing body of evidence supporting this practice for all MCL patients after ASCT,...
From the Journals
TP53 mutations could help stratify MCL patients
The study looks at response to standard-of-care regimens in younger patients.
From the Journals
Lenalidomide shows clinical activity in relapsed/refractory MCL
The observational study highlights the potential of the drug in a population of hard-to-treat patients.
News
FDA approves acalabrutinib for second-line treatment of MCL
Approval was based on an 81% overall response rate in a phase 2 trial of 124 patients who had received at least one prior therapy.
From the Journals
Irradiation safe, effective as chemotherapy before cell transplant in mantle cell lymphoma
Total-body irradiation shown to be not only effective, but safe in autologous stem cell transplantation preparation in MCL.
From the Journals
Rare type of MCL mimics Castleman disease
Careful flow cytometric analysis is recommended when a histopathological diagnosis is made.
From the Journals
VCR regimen showed efficacy in mantle cell and indolent lymphomas
In the 24-patient study, the 2-year progression-free survival rate was 82% and 54% respectively for MCL and iNHL patients, respectively.